Organon, a women's healthcare company spun off from Merck, completed an acquisition of Alydia Health, a medical device company, June 16.
Alydia Health specializes in medical devices to treat postpartum hemorrhage. The deal is valued at up to $240 million, including $50 million upfront, $165 million upon the closing of the deal, and $25 million in milestone payments.
"Organon's acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women's unmet medical needs," Kevin Ali, CEO of Organon, said in a news release. "This acquisition brings us one step closer to our vision of a better and healthier everyday for every woman around the world."
Organon spun off from Merck June 3.
Read the full news release here.